Abstract

NRF2/NF-ΚB CROSS TALK: A PUTATIVE TARGET FOR DEVELOPING NOVEL ANTI-INFLAMMATORY AGENTS

Lokesh Gambhir*

Abstract

Persistent and prolonged inflammation is the root of multiple immune disorders. Though multiple treatment modalities are available based on diverse strategies, still a dire need exists to develop novel antiinflammatory agents with least side effects. Among the potent strategies employed, activation of Nrf2 and inhibition of NF-κB pathway independently have yielded promising results of immunosuppression. The present article highlights the potential of targeting the cross talk between these two redox sensitive immunoregulatory transcription factors to develop novel repository of antiinflammatory agents. Developing an agent that can activate Nrf2 pathway to confer anti-inflammatory/cytoprotective effects and simultaneously inhibit NF-κB pathway to curb inflammation would be superlative over other available modalities.

Keywords: KEAP-1, IKK?, chronic inflammation, prooxidants.